GH/IGF-1 axis is one of the main regulator of both bone modeling and remodeling. Therefore, GH deficient (GHD) patients have a derangment in these processes leading to impaired linear growth with delayed stature, reduced peak bone acquisition, reduced bone size, decrease in bone turnover, low bone mass, osteoporosis and increased fracture risk in adults. GH replacement therapy can restore a normal bone linear growth in children and can improve bone mass, reducing the fractures in GHD patients, whereas its application in treating osteoporosis in non-GHD patients is still controversial.
|Titolo:||Osteoporosis in GH deficiency|
TRIGGIANI, Vincenzo (Corresponding)
|Data di pubblicazione:||2019|
|Appare nelle tipologie:||2.1 Contributo in volume (Capitolo o Saggio)|